| Accession |
PRJCA027947 |
| Title |
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer |
| Relevance |
Medical |
| Data types |
Genome sequencing and assembly
|
| Organisms |
Homo sapiens
|
| Description |
This is a Phase III, double-blind, randomised study assessing the efficacy of capivasertib+paclitaxel vs placebo+paclitaxel as first-line treatment in patients with histologically confirmed, locally advanced (not amenable to resection with curative intent) or metastatic TNBC in the overall population and in the PIK3CA/AKT1/PTEN-altered sub-population (altered subgroup). 'PIK3CA/AKT1/PTEN-altered' refers to a prespecified subgroup of patients whose tumours harbour qualifying activating mutation in PIK3CA or AKT1 and/or qualifying inactivating alteration in PTEN. |
| Sample scope |
Multiisolate |
| Release date |
2024-07-10 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| AstraZeneca
|
|
2022LB00050/2022LB00051
|
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer
|
|
|
| Submitter |
Shusen
Wang (wangshs2019@163.com)
|
| Organization |
Sun Yat-sen University Cancer Center |
| Submission date |
2024-07-09 |
